While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

Black History Month may have passed, but a local museum is continuing to pay homage to historical movements with some new exhibits. The Museums, 3406 Frederick Ave., is working on an interactive Civil ...

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...

Amplia working on treating fibrotic cancers and IPF Also working to find a new treatment for IPF is Amplia (ASX:ATX), which is headed by experienced drug discovery leader Dr Chris Burns ...

Chris Moore, president of Veeva Europe ... A case study fireside chat: GSK, BioNTech, and Boehringer Ingelheim Just last week, Boehringer Ingelheim fully committed to Veeva Vault CRM.

Chief executive Chris Boerber described the FDA approval ... Other therapies hoping to provide a new way to treat schizophrenia include Boehringer Ingelheim's selective glycine transporter 1 ...

On Tuesday, Boehringer Ingelheim’s Empagliflozin became off-patent in India. Major domestic drugmakers are expected to launch their generic versions soon. According to the company’s statement ...

ST. JOSEPH, Mo. — Black History Month may have passed, but a local museum is continuing to pay homage to historical movements with some new exhibits. The St. Joseph Museums, 3406 Frederick Ave ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...